A product is termed as biosimilar product, if it is a biological product with similar characteristics as that of a reference biological product, which possesses approval from agencies such as FDA. There would not be any major clinical difference in effectiveness and safety as that of reference product. Biosimilar products are made of complex molecules with high molecular weight produced through genetic engineering in living cells. Biologics drugs are costlier than respective chemical drugs. Biosimilar drugs can save around 30 to 40 % in terms of price relative to the respective biologics drugs. Biosimilars are useful for the treatment of illnesses such as anemia, autoimmune diseases, cancer, diabetes, growth hormone deficiencies, hematological diseases, kidney failure, rheumatoid arthritis and others. For the manufacturing of biosimilars, manufacturers have to develop environments that are ideal for the living cells, which remain sensitive to environmental conditions. Moreover, they need to develop distinctive process to entice the living cells for producing similar outcome to a prevalent biological treatment. The substitution of biological drugs with biosimilar drugs can save lot of money for public health care sector and patients. The regulatory authorities in developed nations are promoting biosimilar products.

The global Biosimilar market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of 25.0% during 2019-2025.
This report focuses on Biosimilar volume and value at global level, regional level and company level. From a global perspective, this report represents overall Biosimilar market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Biosimilar in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Biosimilar manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Allergan plc
BIOCAD
Biocon
BioXpress Therapeutics
Boehringer Ingelheim
Celltrion
Coherus BioSciences
Dr. Reddy’s Laboratories
Genor BioPharma
Intas Pharmaceuticals Limited
Novartis
Pfizer
Reliance Life Sciences

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Human Growth Hormones
Monoclonal Antibodies
Insulin
Peptides
Erythropoietin
Others

Segment by Application
Oncology
Chronic and Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Others